These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. [Farnesyl transferase inhibitors (anti-Ras). A new class of anticancer agents]. Levy R Presse Med; 1995 Apr 15-22; 24(15):725-9. PubMed ID: 7784406 [TBL] [Abstract][Full Text] [Related]
45. Relative Contributions of Prenylation and Postprenylation Processing in Cryptococcus neoformans Pathogenesis. Esher SK; Ost KS; Kozubowski L; Yang DH; Kim MS; Bahn YS; Alspaugh JA; Nichols CB mSphere; 2016; 1(2):. PubMed ID: 27303728 [TBL] [Abstract][Full Text] [Related]
47. Substrate specificity determinants in the farnesyltransferase beta-subunit. Trueblood CE; Boyartchuk VL; Rine J Proc Natl Acad Sci U S A; 1997 Sep; 94(20):10774-9. PubMed ID: 9380709 [TBL] [Abstract][Full Text] [Related]
48. Conversion of protein farnesyltransferase to a geranylgeranyltransferase. Terry KL; Casey PJ; Beese LS Biochemistry; 2006 Aug; 45(32):9746-55. PubMed ID: 16893176 [TBL] [Abstract][Full Text] [Related]
49. Post-translational modifications of p21rho proteins. Adamson P; Marshall CJ; Hall A; Tilbrook PA J Biol Chem; 1992 Oct; 267(28):20033-8. PubMed ID: 1400319 [TBL] [Abstract][Full Text] [Related]
50. Selective cytotoxicity of farnesylamine to pancreatic carcinoma cells and Ki-ras-transformed fibroblasts. Ura H; Obara T; Shudo R; Itoh A; Tanno S; Fujii T; Nishino N; Kohgo Y Mol Carcinog; 1998 Feb; 21(2):93-9. PubMed ID: 9496909 [TBL] [Abstract][Full Text] [Related]
51. Farnesyl protein transferase inhibitors as potential cancer chemopreventives. Kelloff GJ; Lubet RA; Fay JR; Steele VE; Boone CW; Crowell JA; Sigman CC Cancer Epidemiol Biomarkers Prev; 1997 Apr; 6(4):267-82. PubMed ID: 9107432 [TBL] [Abstract][Full Text] [Related]
52. Protein prenylation: key to ras function and cancer intervention? Khosravi-Far R; Cox AD; Kato K; Der CJ Cell Growth Differ; 1992 Jul; 3(7):461-9. PubMed ID: 1419908 [No Abstract] [Full Text] [Related]
53. Amino acid residues that define both the isoprenoid and CAAX preferences of the Saccharomyces cerevisiae protein farnesyltransferase. Creating the perfect farnesyltransferase. Caplin BE; Ohya Y; Marshall MS J Biol Chem; 1998 Apr; 273(16):9472-9. PubMed ID: 9545274 [TBL] [Abstract][Full Text] [Related]
54. The perplexing case of the geranylgeranyl transferase-deficient mouse. Philips MR J Clin Invest; 2011 Feb; 121(2):510-3. PubMed ID: 21266773 [TBL] [Abstract][Full Text] [Related]
55. The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity. Basso AD; Mirza A; Liu G; Long BJ; Bishop WR; Kirschmeier P J Biol Chem; 2005 Sep; 280(35):31101-8. PubMed ID: 16006564 [TBL] [Abstract][Full Text] [Related]
56. Inhibition of Ras prenylation: a signaling target for novel anti-cancer drug design. Lerner EC; Hamilton AD; Sebti SM Anticancer Drug Des; 1997 Jun; 12(4):229-38. PubMed ID: 9199657 [TBL] [Abstract][Full Text] [Related]
57. Posttranslational Modifications of RAS Proteins. Ahearn I; Zhou M; Philips MR Cold Spring Harb Perspect Med; 2018 Nov; 8(11):. PubMed ID: 29311131 [TBL] [Abstract][Full Text] [Related]
58. Anchoring of bacterial effectors to host membranes through host-mediated lipidation by prenylation: a common paradigm. Al-Quadan T; Price CT; London N; Schueler-Furman O; AbuKwaik Y Trends Microbiol; 2011 Dec; 19(12):573-9. PubMed ID: 21983544 [TBL] [Abstract][Full Text] [Related]